Evidence map›Paper›PMID 41152533›Full record

ArticleScientific reports2025

Pharmacovigilance study of adverse events of vedolizumab based on the FAERS database.

Guanghui Yuan, Jie Liu, Yi Xu, Zhaowei Shan

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Guanghui Yuan *Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, No.155, Hanzhong Road, Qinhuai District, Nanjing, Jiangsu Province, China.
Jie Liu *Mufushan Community Health Service Center of Gulou District, Nanjing, Jiangsu Province, China.
Yi XuAffiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, No.155, Hanzhong Road, Qinhuai District, Nanjing, Jiangsu Province, China. xuyi999999999@163.com.
Zhaowei ShanAffiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, No.155, Hanzhong Road, Qinhuai District, Nanjing, Jiangsu Province, China. ygh13809034614@163.com.

Funding

Academic Promotion Project for Department Director of Jiangsu Provincial Hospital of Traditional Chinese Medicine Y2022ZR07China Academy of Chinese Medical Sciences(CACMS) Innovation Fund CI2023C011LHJiangsu Province Traditional Chinese Medicine Science and Technology Development Plan ZD202407
6 · The paper itself

Abstract

This study aims to assess the adverse event profile of vedolizumab (Entyvio

Indexed as

Adverse Drug Reaction Reporting SystemsAntibodies, Monoclonal, HumanizedDrug-Related Side Effects and Adverse ReactionsGastrointestinal AgentsPharmacovigilanceAdolescentAdultAgedBayes TheoremDatabases, FactualFemaleHumansMaleMiddle AgedUnited StatesYoung AdultAntibodies, Monoclonal, HumanizedGastrointestinal AgentsvedolizumabAdverse eventFAERSPharmacovigilanceVedolizumab

Identifiers

PMID41152533
PMCPMC12568951

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.